Cardio-Cerebrovascular Protective Effects of Valsartan in High-Risk Hypertensive Patients With Coronary Artery Disease (from the Kyoto Heart Study)

详细信息    查看全文

• 作者：Jun Shiraishi ; MD ; PhD^a ; ^{risa11221998@yahoo.co.jp} ; Takahisa Sawada ; MD ; PhD^b ; Masahiro Koide ; MD ; PhD^b ; Hiroyuki Yamada ; MD ; PhD^b ; Hiroaki Matsubara ; MD ; PhD^b ; Kyoto Heart Study Group
• 刊名：The American Journal of Cardiology
• 出版年：2012
• 出版时间：1 May, 2012
• 年：2012
• 卷：109
• 期：9
• 页码：1308-1314
• 全文大小：1481 K

文摘

The objective was to examine whether previous coronary artery disease (CAD) influences the add-on effects of the angiotensin II receptor blocker (ARB) valsartan on cardio-cerebrovascular morbidity and mortality in high-risk hypertensive patients who participated in the Kyoto Heart Study. The primary end point was the same as in the main study: a composite of new-onset and/or worsening of cardiovascular and cerebrovascular events. Median follow-up was 3.27 years. According to the presence of previous CAD at baseline, the study population was divided into 2 groups (with CAD, n = 707; without CAD, n = 2,324) in which primary end-point events occurred more frequently in patients with CAD than in patients without CAD (15.1 % vs 5.6 % , hazard ratio [HR] 2.68, 95 % confidence interval [CI] 2.11 to 3.42). Add-on valsartan significantly decreased the occurrence of the primary end-point events in patients with CAD (11.3 % vs 19.0 % , HR 0.59, 95 % CI 0.41 to 0.85) and without CAD (3.7 % vs 7.6 % , HR 0.49, 95 % CI 0.34 to 0.70) compared to non-ARB treatment. In the presence of previous CAD, patients with valsartan add-on treatment had a significantly lower prevalence of angina pectoris and stroke than those with non-ARB treatment, whereas the valsartan add-on effects on angina and stroke were not significant in the absence of CAD. Changes in blood pressure during the follow-up period did not differ significantly between study subgroups. In conclusion, in the presence or absence of previous CAD, valsartan add-on treatment prevented more cardio-cerebrovascular events than conventional non-ARB treatment in high-risk hypertensive patients. In addition, valsartan add-on treatment conferred not only an antianginal effect but also stroke prevention exclusively in hypertensive patients with CAD compared to those without CAD.